MAP2K7 and renal cell carcinoma: We saw that 10 nM of the MEK inhibitor GSK1120212 (hereafter called GSK212) was sufficient to fully inhibit MEK activity as assessed by pERK T202/Y204 in several RCC cell lines (Figure 4B).